As if patient identification and engagement weren't challenging enough, add in a rare disease study, and it can feel like a daunting process. Patient populations are small and widely dispersed around the globe, and finding the proper sites to support these patients is difficult. As an emerging biopharma company, limited resources can make these challenges that much harder.
In this webinar, Dr. Cynthia Jackson, Jessica Perry, and Nobu Kawasaki, experts in the study of rare diseases and patient recruitment at QuintilesIMS, will share their thoughts on how emerging biopharma companies can better impact enrollment and shorten the timelines of rare disease studies. Key themes of the discussion include:
Dr. Cynthia Jackson, D.O., FAAP
Vice President and Head, Pediatric and Rare Disease Centers of Excellence
Associate Director, Patient Recruitment Programs